Trials / Completed
CompletedNCT03339089
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 224 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.
Conditions
Timeline
- Start date
- 2018-05-18
- Primary completion
- 2021-07-08
- Completion
- 2021-07-08
- First posted
- 2017-11-13
- Last updated
- 2022-07-08
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03339089. Inclusion in this directory is not an endorsement.